Fundraising Fox
Lumos Pharma
Austin, US · Founded 2014 · Delaware corporation · 49 employees on LinkedIn · 6 known investors
Find your way into Lumos Pharma
Sign up to see every warm intro you have to Lumos Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Lumos Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Lumos Pharma is a clinical-stage biopharmaceutical company developing therapies for rare diseases, with a lead candidate targeting Pediatric Growth Hormone Deficiency. It also pursues partnerships to in-license or acquire additional rare disease therapeutic candidates for development and commercialization.
Founders & leadership
Lumos Pharma was founded in 2014 by Richard John Hawkins.
RJ
Richard John HawkinsFounder
JC
John C. McKewPresident and Chief Scientific OfficerJohn C. McKew is President and Chief Scientific Officer of Lumos Pharma. He has over 17 years of pharmaceutical research experience, including leading drug discovery and development programs in rare diseases and neglected tropical diseases at the NIH, and previously managed multi-site chemistry teams that advanced clinical candidates in inflammatory and cardiovascular disease areas.
P"
Pisit "Duke" PitukcheewanontChief Medical OfficerPisit Pitukcheewanont is a pediatric endocrinologist and clinical researcher with over 25 years of experience; he holds faculty positions at the Keck School of Medicine at USC and served as Clinical Director of the Pediatric Bone Program at Children's Hospital Los Angeles, and has authored over 70 peer-reviewed publications in pediatric endocrinology and metabolic bone disorders.
LL
Lori LawleyChief Financial OfficerLori Lawley is Chief Financial Officer at Lumos Pharma and brings over 15 years of financial operations and accounting experience across startups, global enterprises, and industries including software, biotech, and manufacturing.
BP
Brad PowersChief Compliance Officer and General CounselHe holds a J.D., a Master's degree in Bioinformatics and Computational Biology, and a Bachelor's degree in Biology, with prior general counsel experience in biotechnology, pharmaceutical, and manufacturing organizations across public and private settings.
CM
Campbell MurrayExecutive ChairmanCampbell Murray is Executive Chairman of Lumos Pharma, a clinical-stage biopharmaceutical company developing therapies for rare diseases. He has experience in biotech leadership and venture capital investment in the life sciences sector.
Board
KM
Kevin M. LalandeBoard director
EJ
Edward J. MathersBoard director
GG
George Gilbert CloydBoard director
RH
Robert HeftBoard director
JS
Jon S. SaxeBoard director
Investors · 6
New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M
How we know: funding news · open dataset · 5k.vc investor directory · Not right? Tell us
Clarus VenturesreportedMenlo Park
How we know: funding news · Not right? Tell us
Deerfield Management CompanyreportedNew York
How we know: funding news · Not right? Tell us
Sante VenturesreportedAustin · $2M – $6M
How we know: a partner's Signal profile · funding news · Not right? Tell us
Wellcome TrustreportedLondon
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$47M disclosed across 2 rounds · 2014–2016
▶$34MraisedApr 2016 · 6 investors · PharmaceuticalsRule 506(b)
▶$34MraisedApr 2016 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michele ParkDirector
- G. Gilbert CloydDirector
- Kevin LelandeDirector
- Robert HeftDirector
- Cameron WheelerDirector
- Richard John HawkinsExecutive Officer, Director
- Edward MathersDirector
- Jon S. SaxeDirector
- Tracy SaxtonDirector
- Offering amount
- $34M
- Amount sold
- $34M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$13MraisedMay 2015 · 5 investors · PharmaceuticalsRule 506(b)
▶$13MraisedMay 2015 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kevin M. LalandeDirector
- Richard John HawkinsExecutive Officer, Director
- George Gilbert CloydDirector
- Robert HeftDirector
- Jon S. SaxeDirector
- Edward J. MathersDirector
- Offering amount
- $13M
- Amount sold
- $13M
- First sale
- Jan 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Lumos Pharma do?
- Lumos Pharma is a clinical-stage biopharmaceutical company developing therapies for rare diseases, with a lead candidate targeting Pediatric Growth Hormone Deficiency. It also pursues partnerships to in-license or acquire additional rare disease therapeutic candidates for development and commercialization.
- Who founded Lumos Pharma?
- Lumos Pharma was founded by Richard John Hawkins in 2014.
- Who are Lumos Pharma's investors?
- Lumos Pharma's investors include New Enterprise Associates (NEA), Clarus Ventures, Deerfield Management Company, Sante Health Ventures, Sante Ventures, Wellcome Trust.
- How much funding has Lumos Pharma raised?
- Lumos Pharma has disclosed $47M raised across 2 rounds.
- Where is Lumos Pharma headquartered?
- Lumos Pharma is headquartered in Austin, US.